Israeli company Galmed Pharmaceuticals Ltd., which is developing proprietary drugs for the treatment of fatty liver disease, is planning a multi-million IPO at a company value of $100 million. “Globes” reports that the decision will be made by October, and if the decision is taken to go ahead, the IPO will be held in December.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
![](https://nocamels.com/wp-content/uploads/2018/02/INSIGHTEC-350x180.jpg)
Israeli Ultrasound Creator Collaborating On Neuroscience R&D In US
September 05, 2024
![The Weizmann Institute of Science. Photo via the Weizmann Institute of Science](https://nocamels.com/wp-content/uploads/2018/07/weizmann-350x252.jpg)
Weizmann In World’s Top 10 For Biomedical And Overall Research
September 05, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/Depositphotos_75148477_L-350x228.jpg)
Israeli NGO Begins New Mental Health Training In Ukraine
September 04, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/17123254699_79ff768811_ks-350x213.jpg)
Nonprofit Launches Loans For Stricken Northern Israel Businesses
September 04, 2024
Facebook comments